Cell Therapeutics’ Adaptive Trials For Lymphoma Treatment Pixantrone Could Meet Endpoints Early

Meeting endpoints early would allow NDA filing in second half of 2008, CEO James Bianco tells “The Pink Sheet” DAILY.

More from Archive

More from Pink Sheet